Blood packs successfully delivered in NHSBT drone trial

Part of a series of tests to demonstrate the viability of transporting medical supplies by drone, the trial saw ten units of packed blood cells transported on a 68km journey between Northumbria Healthcare NHS Foundation Trust’s Wansbeck Hospital and Alnwick Infirmary. At the same time, ten identical packs were transported between the two points via road, travelling a distance of 74.6km. 

In total, ten separate journeys were undertaken between Wansbeck Hospital and Alnwick Infirmary and back again – five by ground and five by air. The packs were then analysed to assess factors including concentration of potassium and the percentage of haemolysis or destruction of the blood cells. Results showed that drone delivery did not influence the blood’s quality or longevity and could therefore be considered a safe mode of transport. 

“We're pleased the trial has clearly demonstrated drone delivery of blood packs is feasible and safe, supporting the potential for drones to transport critical healthcare supplies to patients, at the right time and with fewer emissions,”  Hammad Jeilani, medical director and co-founder at Apian said in a statement. "We're excited to continue working with NHSBT in future trials, expanding our research and exploring how drones can transform the future of NHS blood logistics.”

As well as demonstrating the safety of transporting blood packs by drone, it was also the first time that blood packs have been delivered by drones flying beyond the visual line of sight, meaning the pilot cannot see the physical drone as it travels, instead monitoring it remotely. It’s claimed the trials were also the longest ever beyond visual line of sight drone flights in UK.

“We’re excited to be a part of this joint study with Apian, by supplying and testing the blood used, to see if blood would maintain its suitability for transfusion when flown further than ever before via drone,” said Gail Miflin, chief medical officer at NHS Blood and Transplant.

“The results of this first trial are very promising, showing no compromise to the safety of the blood. We look forward to seeing the outcomes from the next round of the study.”